The Journal of the Korea Contents Association (한국콘텐츠학회논문지)

The Korea Contents Association (한국콘텐츠학회)
권호 표지
DOI QR코드

DOI QR Code

Adverse Drug Reactions of Dextran 40 Treated to the Cerebral Infarction Patients

뇌경색 환자에게 사용된 덱스트란 40의 부작용 분석

  • 김재현 (전주비전대학교 간호학부/전주예수병원 의약품부작용위원회)
  • Received : 2016.05.12
  • Accepted : 2016.07.15
  • Published : 2016.09.28
Download PDF
⟨ Previous Next ⟩

Abstract

Adverse drug reactions(ADRs) were caused by dexran 40 in patient with ischemic stroke and related 22 patients reported to formal ADRs at Jesus Hospital in Jeonju. This study was aimed to search ADRs related factors, type and the degree associated with dextran 40. Adverse Effects of Dextran 40 is including marked hypotension, nausea, dyspnea, generalized urticaria, fever and pulmonary edema. The average hospitalization period was 20 days and it was extended 26.8%. ADRs of Dextran 40 to incidence is 12.4%, and 9 persons(28.1%), itching, rash was 7 people (21.9%). Dextran induced ADRs reaction may be reported on early injection period and first time shot, but adverse drug reactions occurred after 4 days in 4 patients(18.2%). US FDA has recommanded that Dextran 1 significantly reduces the incidence of severe ADRs in USA. Because low molecular weighted dextran 1 prevented dextran molecules from combined Ig G completely. In Korea. Generally not yet introduced dextran 1, active use dextran 1 is able to be a good way in order to reduce ADRs of dextran 40.

뇌경색으로 입원하여 덱스트란 40을 투여받고 약물유해반응이 발생하여 의약품 부작용 보고서에 의해 보고된 전주예수병원 환자 22명을 대상으로 하였다. 이 연구의 목적은 뇌경색으로 덱스트란 40을 투여받은 환자를 대상으로 덱스트란 40의 약물유해반응과 부작용을 조사 및 보고함으로써 약물유해반응을 줄이기 위한 방안을 제시하고자 한다. 덱스트란의 부작용은 저혈압, 오심, 호흡곤란, 전신적인 두드러기, 열이고 과량 투여 시 폐부종을 유발한다. 평균 입원 기간은 20일로 입원환자의 26.8%가 입원기간의 연장을 경험하였고 덱스트란 40의 약물유해반응 발생률은 12.4%였고, 9명(28.1%)이 itching, rash는 7명(21.9%)이었다. 주입초기에, 초회 주사에서 덱스트란 아나필락틱 반응이 나타날 수 있다고 보고되고 있으나 투여 후 4일째에 부작용이 발생한 환자가 4명으로 18.2%에 이른다. 우리나라에는 덱스트란 1이 아직 널리 알려져 있지 않지만 미국 FAD에서는 사용을 권장하고 있으며, 덱스트란 40의 약물유해반응을 줄이기 위해서는 덱스트란 1의 사용을 고려해 볼 필요가 있다.

Keywords

References

  1. http://www.bokjiro.go.kr/nwel/welfareinfo/livwelnews/news/retireveNewsDetail.do?boardSid=308&dataSid=6215507
  2. J. A. Farina Jr, C. E. Piccinato, A. D. Camppos, and M. A. Rossi, "Comparative study of isovolemic hemodilution with 3% albumin, dextran-40, and prophylactic enoxaparin (LMWH) on thrombus formation at venous microanastomosis in rats," Microsurgery, Vol.26, No.6, pp.456-466, 2006. https://doi.org/10.1002/micr.20270
  3. K. Gombocz, A. Beledi, N. Alotti, G. Kecskes, V. Gabor, L. Bogar, T. Koszegi, and J. Garai, "Influence of dextran-70 on systemic inflammatory response and myocardial ischemia-reperfusion following cardiac operations," Crit Care, Vol.11, No.4, p.R87, 2007. https://doi.org/10.1186/cc6095
  4. KFDA, 2006 Drug reevaluate major cases. Available from: http://www.ikwn.co.kr/bbs/list.html
  5. L. Jaemin, "Plasma volume expanders and intraoperative fluid therapy," Korean J Anesthesiol, Vol.56, No.5, pp.483-491, 2009. https://doi.org/10.4097/kjae.2009.56.5.483
  6. Drug Administration Protocol-Dextran 40 (Rheomacrodex), Liverpool Health Service Intensive Care Unit, First Issued December 2002.
  7. G. Biesenbach, W. Kaiser, and J. Zazgornik, "Incidence of acute oligoanuric renal failure in dextran 40 treated patients with acute ischemic stroke stage III or IV," Ren Fail, Vol.19, No.1, pp.69-75, 1997. https://doi.org/10.3109/08860229709026261
  8. A. P. Bhatt, V. T. Neppalli, E. A. Kelley, A. J. Schlueter, and C. P. Thomas, "Dextran Removal by Plasmapheresis in a Kidney-Pancreas Transplant Recipient With Dextran 40-Induced Osmotic Nephrosis," Am J Kidney Dis, Vol.57, No.4, pp.621-623, 2011. https://doi.org/10.1053/j.ajkd.2010.10.057
  9. C. E. Zinderman, L. Landow, and R. P. Wise, "Anaphylactoid reactions to Dextran 40 and 70: Reports to the United States Food and Drug Administration, 1969 to 2004," Journal of Vascular Surgery, Vol.43, No.5, pp.1004-1009, 2006. https://doi.org/10.1016/j.jvs.2006.01.006
  10. E. C. Davies, C. F. Green, S. Tayler, P. R. Williamson, D. R. Mottram, and M. Pirmohamed, "Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patients-episodes," PLoS One, Vol.4, No.e4439, 2009.
  11. K. G. Ljungstrom, H. Renck, K. Stanberg, H. Hedin, W. Richter, and E. Wirdelov, "Adverse reactions to dextran in Sweden," Acta Chir Scand, Vol.149, pp.256-62, 1983.
  12. Y. A. Do and S. H. Lee, "Adverse drug reactions with oseltamivir treatment in the South Korea outbreak of 2009 pandemic influenza A(H1N1), Kor J Clin Pharm, Vol.21, No.4, pp.353-363, 2009.
  13. H. Kawano, K. Nomura, S. Kawahito, N. Ohshita, K. Tanaka, and S. Oshita, "Dextran-induced anaphylactic shock during general anesthesia: a case repor," Masui, Vol.61, No.11, pp.1265-8, 2012
  14. KIMS. dextran. Available from: http://www.kimsonline.co.kr./131_UnifiedSearch/DrugSearchList.aspx?src=header&PageSearch=T&PageWord=dextran(Last accessed on February 15, 2013).
  15. K. S. Lee, M. H. Kong, S. H. Chang, H. Cho, H. J. Lim, and N. S. Kim, "A Case Report of Anaphylactoid Reaction to Dextran 40," Korea Journal of Anesthesiology, Vol.27, No.12, 1822-26, 1994. https://doi.org/10.4097/kjae.1994.27.12.1822
  16. S. H. Cho, "Hypersensitivity Reaction," BioWave, Vol.7, No.3, 2005.
  17. J. Lazarou, B. H. Pomeranz, and P. N. Corey, "Incidence of adverse drug reactions in hospitalized patients: a meter-analysis of prospective studies," JAMA, Vol.279, No.15, pp.1200-1205, 1998. https://doi.org/10.1001/jama.279.15.1200
  18. K. G. Ljungstrom, B. Willam, and H. Heidin, "Hapten inhibition of dextran anaphylaxis. Nine years of post-marketing surveillance of dextran 1," Ann Fr Anesth Reanim, Vol.12, No.2, pp.19-22, 1993. https://doi.org/10.1016/S0750-7658(16)30019-3